Dopamine neurotransmission and treatments for parkinson’s disease in the molecular biology era

European Neurology

Volumn 38, Issue 1, 1997, Pages 2-5

  Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

3 O Methyldopa; Absorption of levodopa; Bromocriptine; Decarboxylase inhibitor; Dopamine agonist; Dopamine metabolism; Dopamine receptor subtypes; Gene therapy

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR; HOMOVANILLIC ACID; LEVODOPA; RECEPTOR SUBTYPE;

BLOOD BRAIN BARRIER; CONFERENCE PAPER; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; MOLECULAR BIOLOGY; MOTOR PERFORMANCE; NEUROTRANSMISSION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; DOPA DECARBOXYLASE; DOPAMINE; DOPAMINE AGONISTS; ENZYME INHIBITORS; HUMANS; LEVODOPA; PARKINSON DISEASE; SYNAPTIC TRANSMISSION;

EID: 0030804957     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113435     Document Type: Article

References (39)

1. Ogawa N: Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med Okayama 1995:49:1-11.
2. Korten JJ, Keyser A, Joosten EM, Gabreels FJM: Madopar versus Sinemet: A clinical study on their effectiveness. Eur Neurol 1975; 13:65-71.
3. Greenacre JK, Coxon A, Petrie A, Reid JL: Comparison of levodopa with carbidopa or bcnscrazide in parkinsonism. Lancet 1976:ii: 381-384.
4. Ogawa N, Yamamoto M: Various peripheral and central factors affect on efficacy of levodopa. Jpn J Neuropsvchopharmacol 1995;17: 885-892.
5. Lieberman A, Estey E, Gopinathan G, Ohashi T, Sauter A, Goldstein M: Comparative effectiveness of two extracercbral DOPA decarboxylase inhibitors in Parkinson disease. Neurology 1978;28:964-968.
6. Rinne UK, Molsa P: Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 1979:29:1584-1589.
7. Inoue N, Mivoshi S: Amelioration of wearing-off phenomenon by exchanging of levodopa/DCI drugs. Neurol Med (Tokyo) 1994:40:313.
8. Wade DN, Mearrick PT, Morris JL: Active transport of L-dopa in the intestine. Nature 1973:242:463-465.
9. Mearrick PT, Wade DN, Birkett DJ, Morris J: Metoclopramide, gastric emptying and L-dopa absorption. Aust NZJ Med 1974:4:144-148.
10. Neira WD, Sanchez V, Mena MA, de Yebens JG: The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson’s disease. Mov Disord 1995;10:66-70.
11. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E: Effects of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995:10:81-84.
12. Ogawa N, Takayama H, Kuroda H, Ishibe Y, Aoyama T: Long-term administration of dom-peridonc in Parkinson’s disease. Jpn Pharmacol Thcr 1985;13:7339-7344.
13. Mena I, Cotzias GC: Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975:292:181-184.
14. Juncos JL, Fabbrini G, Mouradian MM, Serratic C, Chase TN: Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987:44:1003-1005.
15. Kurlan R: Dietary therapy for motor fluctuations in Parkinson's disease. Arch Neurol 1987: 44:1119-1121.
16. Pincus JH, Barry K: Protein redistribution diet restores motor function in patients with dopa-resistant 'oil' periods. Neurology 1988,38:481-483.
17. Riley D, Lang AE: Practical application of low-protein diet for Parkinson's disease. Neurology 1988:38:1026-1031.
18. Berry EM, Growden JH, Wurtman JJ, Caballero B, Wurtman RJ: A balanced carbohydrate: Protein diet in the management of Parkinson's disease. Neurology 1991;41:1295-1297.
19. Lcenders KL, Palmer AJ, Quinn N, Clark JC, Fimau G, Garnett ES, Nahmias C, Jones T. Marsden CD: Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986:49:853-860.
20. Tsui JK, Ross S, Poulin K, Douglas J, Postnikot TD, Caine S, Woodward W, Caine DB: The effect of dietary protein on the efficacy of L-dopa: A double-blind study. Neurology 1989; 39:549-552.
21. Nutt JG, Woodward WR, Hammcrstad JP, Carter JH: The 'on-off phenomenon in Parkinson's disease. N Engl J Med 1984:310:483-488.
22. Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Martinelli P: Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-537.
23. Schuh LA, Bennett JP: Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993:43:1545-1550.
24. Nutt JG, Woodward WR, Gancher ST, Merrick D: 3-O-Methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21:584-588.
25. Febbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN: 3-O-Methyldopa and motor fluctuations in Parkinson's disease. Neurology 1987;37:856-859.
26. Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-183.
27. Ogawa N, Asanuma M, Tanaka K, Matsuura K, Iida K, Yamamoto M: Effects of bromocriptine on dopamine turnover with or without levodopa. J Int Med Res 1996;24:271-277.
28. Mouradian MM, J uncos JL, Fabbrini G, Schlegel J, Barrko JJ, Chase TN: Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms. Part II. Ann Neurol 1988:24: 372-378.
29. Ogawa N, Yamawaki Y, Kuroda H, Takayama H, Ota Z: Differences in the effects of levodopa and bromocriptine on rat striatal dopamine receptors. Neurosciences 1984:10:259-266.
30. 123I-IBZM-SPECT. Mov Disord 1993;8:453-458.
31. Kofman OS: Are levodopa 'drug holidays' justified? Can J Neurol Sci 1984; 11 (suppl 1):206-209.
32. Cedarbaum JM: Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Neurol Clin 1990;8:31-49.
33. Nutt JG, Woodward W, Hammerstad JP, Gancher ST: Dose tolerance develop to levodopa? Comparison of 2-and 21-H levodopa infusions. Mov Disord 1993;8:139-143.
34. Robertson HA, Peterson MR, Worth GG: Synergic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist. CY 208-243. Brain Res 1992:593:332-334.
35. 2. dopamine receptors is necessary for full expression of post synaptic effects of dopamine agonists: A neurophysiological study. Brain Res 1987;400:205-218.
36. 2 dopamine receptor mechanism in dopaminergic behaviors. Clin Ncuropharmacol 1988:11:221-231.
37. Strange PG: New insights into dopamine receptors in the central nervous system. Neuro-chem Int 1993;22:223-236.
38. Blum K, Noble EP, Sheridan PJ, Montogomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohs JB: Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990:263:2055-2060.
39. Fisher LJ, Gage FH: Novel therapeutic direction for Parkinson's disease. Mol Med Today 1995;1:181-187.